Hendrick Pagan-Torres
Transplant Hepatology · Ponce, PRNPI 1265896732
Payments from drug & device makers
Across 101 payments — averaging $465.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$42K
- AbbVie$1K
- Gilead$898
- Ipsen Biopharmaceuticals, Inc$537
- Echosens North America, Inc.$413
- Intercept Pharmaceuticals, Inc.$343
- plus $1K from 9 others
What the payments were for
- Consulting fees$3,1637%
- Speaking & faculty fees$33,06870%
- Travel & lodging$3,4437%
- Food & beverage$7,37816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 43 | $42,220 |
| AbbVie | 17 | $1,300 |
| Gilead | 16 | $898 |
| Ipsen Biopharmaceuticals, Inc | 5 | $537 |
| Echosens North America, Inc. | 4 | $413 |
| Intercept Pharmaceuticals, Inc. | 3 | $343 |
| Mirum Pharmaceuticals, Inc. | 2 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $261 |
| Olympus Latin America, Inc. | 2 | $235 |
| Mallinckrodt Hospital Products Inc. | 1 | $128 |
| Akcea Therapeutics, Inc. | 1 | $125 |
| Boston Scientific | 1 | $103 |
| E.r. Squibb & Sons, L.L.C. | 1 | $97 |
| Perspectum Diagnostics Ltd | 1 | $73 |
| GSK | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few transplant hepatology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 19 | $60,640 |
| Dexlansoprazole DrDexlansoprazole | 14 | $2,675 |
| Ursodiol | 24 | $2,651 |
| SuprepSodium, Potassium,mag Sulfates | 21 | $2,459 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $973 |
| Carvedilol | 90 | $550 |
| Pantoprazole Sodium | 57 | $470 |
| Spironolactone | 22 | $329 |
| Esomeprazole Magnesium | 15 | $240 |
| Rosuvastatin Calcium | 16 | $136 |
| Furosemide | 24 | $94 |
| Famotidine | 12 | $50 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.